High-dose sequential (HDS) chemotherapy for high-risk non-Hodgkin's lymphoma: long-term analysis and future developments.

Authors :: Tarella, Corrado
Cuttica, Alessandra
Caracciolo, Daniele
Zallio, Francesco
Ricca, Irene
Bergui, Luciana
Gavarotti, Paolo
Marinone, Carlo
Pagano, Marco
Rossi, Giuseppe
de Crescenzo, Alberto
Salomone, Attillio
Ladetto, Marco
Boccadoro, Mario
Pileri, Alessandro
Source :: Annals of Hematology; Nov2001 Supplement 3, Vol. 80, pB123-B126, 4p
Publication Year :: 2001
Abstract: This article presents information related to high-dose sequential (HDS) chemotherapy for high-risk non-Hodgkin's lymphoma (NHL). High dose chemotherapy with autograft is extensively employed in the management of high-risk lymphoma. This approach is presently first-choice for relapsed high grade NHL and Hodgkin's lymphoma. The original HDS, developed in 1989, includes the sequential delivery of high doses of Cyclophosphamide (CY), Methotrexate and Etoposide given at 15-20 day intervals and finally autograft performed with PBPC collected after CY.

Subjects :: DRUG therapy
LYMPHOMAS
PHARMACOLOGY
THERAPEUTICS
METHOTREXATE
ETOPOSIDE

Full Text Access

Tools